JERUSALEM, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present at the following investor conferences in March 2025.
| Event: | Investor Summit Event |
| Format: | Presentation |
| Date: | March 11, 2025 |
| Time: | 12:00PM – 12:30PM ET |
| Location: | Virtual |
| Event: | Oppenheimer 35th Annual Healthcare MedTech & Services Conference |
| Format: | Presentation |
| Date: | March 17, 2025 |
| Time: | 3:20PM – 3:50PM ET |
| Location: | Virtual |
| Event: | Sidoti Small Cap Conference |
| Format: | Presentation |
| Date: | March 19, 2025 |
| Time: | 11:30AM – 12:00PM ET |
| Location: | Virtual |
Mr. Levy will also be available for 1x1 investor meetings at the conferences. Please reach out to your Investor Summit Group, Oppenheimer, and Sidoti representatives to schedule.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT®
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.61 |
| Daily Change: | -0.01 -0.38 |
| Daily Volume: | 19,470 |
| Market Cap: | US$182.960M |
March 12, 2025 January 27, 2025 December 18, 2024 December 17, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
